Atomoxetine
- Generic Name
- Atomoxetine
- Brand Names
- Strattera
- Drug Type
- Small Molecule
- Chemical Formula
- C17H21NO
- CAS Number
- 83015-26-3
- Unique Ingredient Identifier
- ASW034S0B8
- Background
Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associat...
- Indication
Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Associated Therapies
- -
Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
- Conditions
- Interventions
- First Posted Date
- 2007-10-19
- Last Posted Date
- 2010-08-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 125
- Registration Number
- NCT00546910
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wolfenbüttel, Germany
Treatment Compliance in Children and Adolescents on ADHD Medication
- Conditions
- Interventions
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2009-08-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 518
- Registration Number
- NCT00540826
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bad Homburg, Germany
Atomoxetine Phase 2 Study in Japanese Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD)
- First Posted Date
- 2007-09-17
- Last Posted Date
- 2011-07-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 45
- Registration Number
- NCT00530335
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
- Conditions
- Interventions
- First Posted Date
- 2007-09-12
- Last Posted Date
- 2013-01-29
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 278
- Registration Number
- NCT00528697
- Locations
- 🇺🇸
Site Reference ID/Investigator# 5982, Overland Park, Kansas, United States
🇺🇸Site Reference ID/Investigator# 5981, Northbrook, Illinois, United States
🇺🇸Site Reference ID/Investigator# 5996, Eugene, Oregon, United States
Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
- First Posted Date
- 2007-07-09
- Last Posted Date
- 2017-08-14
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00498173
- Locations
- 🇺🇸
Lurie Center - MassGeneral Hospital, Lexington, Massachusetts, United States
🇺🇸Christian Sarkine Autism Treatment Center at Riley Hospital for Children, Indianapolis, Indiana, United States
Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia
- First Posted Date
- 2007-06-20
- Last Posted Date
- 2017-10-05
- Lead Sponsor
- Research Foundation for Mental Hygiene, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00488163
- Locations
- 🇺🇸
Mount Sinai Hospital, New York, New York, United States
🇺🇸Pilgrim Psychiatric Center, Brentwood, New York, United States
A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine
- First Posted Date
- 2007-05-09
- Last Posted Date
- 2010-01-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 228
- Registration Number
- NCT00471354
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph, Tao-Yuan, Taiwan
A Study Comparing the Effect of Atomoxetine Versus Other Standard Care Therapy on the Long Term Functioning in Attention-Deficit/Hyperactivity Disorder (ADHD) Children and Adolescents
- Conditions
- Interventions
- First Posted Date
- 2007-03-14
- Last Posted Date
- 2010-04-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 399
- Registration Number
- NCT00447278
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sheffield, South Yorkshire, United Kingdom
A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
- Conditions
- Interventions
- First Posted Date
- 2007-01-31
- Last Posted Date
- 2010-11-02
- Lead Sponsor
- Abbott
- Target Recruit Count
- 243
- Registration Number
- NCT00429091
- Locations
- 🇺🇸
Site Reference ID/Investigator# 5964, Burlington, Vermont, United States
🇺🇸Site Reference ID/Investigator# 5960, Clementon, New Jersey, United States
🇺🇸Site Reference ID/Investigator# 5970, Troy, Michigan, United States
Assess the Effectiveness of Atomoxetine in Children With Fetal Alcohol Syndrome and ADD/ADHD
- Conditions
- Interventions
- First Posted Date
- 2007-01-04
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 38
- Registration Number
- NCT00417794
- Locations
- 🇺🇸
OU Child Study Center, Oklahoma City, Oklahoma, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.